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Abstract
The vascular endothelial growth factor-A (VEGF) plays a crucial role in tumor angio-
genesis. Through its primary receptor VEGFR-2, VEGF exerts the activity of a multitask-
ing cytokine, which is able to stimulate endothelial cell survival, invasion and migration 
into surrounding tissues, proliferation, as well as vascular permeability and inflamma-
tion. The core components of VEGF signaling delineate well-defined intracellular routes. 
However, the whole scenario is complicated by the fact that cascades of signals converge 
and branch at many points in VEGF signaling, thus depicting a complex signal transduc-
tion network that is also finely regulated by different mechanisms. In this chapter, we 
present a careful collection of the best-characterized VEGF-induced signal transduction 
pathways, attempting to offer an overview of the complexity of VEGF signaling in the 
context of tumor angiogenesis.
Keywords: VEGF, signaling, angiogenesis, endothelial cells
1. Introduction
It has been over four decades that Judah Folkman hypothesized, demonstrated and empha-
sized the critical importance of angiogenesis in tumor growth [1]. His experimental studies 
showed that in the absence of vascularization a tumor would grow only to a finite size of 
few thousand cells, restricted by the inability of oxygen and nutrients to penetrate the tissue 
beyond the diffusion limits of approximately 1–2 mm. To overcome this passive diffusion-
limited size, the tumor must perturb the physiological state of its environment inducing the 
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so-called angiogenic switch that implicates the transition from quiescent to active endothe-
lium leading to the vascularization of the growing cell mass. The angiogenic switch was ini-
tially hypothesized to be triggered by the production and release of a growth factor called 
TAF (tumor angiogenesis factor) by tumor cells [2]. Indeed, the explosive growth in tumor 
angiogenesis research identified and characterized a number of angiogenic inducers. Among 
them, vascular endothelial growth factor (VEGF) is recognized as the major tumor angiogen-
esis factor [3].
VEGF family consists of five secreted proteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placental growth factor). In terms of endothelial biology and tumor angiogenesis, VEGF-A 
(hereafter referred as VEGF)—in particular VEGF-A
165
—is considered to be the most physi-
ologically relevant form. VEGF angiogenic potential is strictly dependent on its multifunc-
tional activity. Indeed, the coordinated arrangement of endothelial cells to form and maintain 
new vascular tubes requires the induction of vascular permeability, endothelial cell migra-
tion, proliferation and survival. These biological responses take place in the endothelium via 
a complex network of intracellular signal transduction pathways, mainly mediated by VEGF-
induced VEGF receptor 2 (VEGFR-2) activation [4].
In this chapter, after a short historical synopsis of Judah Folkman’s hypotheses and main 
discoveries in the field of tumor angiogenesis, we will present a careful collection of the best 
characterized VEGF-induced signal transduction mechanisms, attempting to offer an over-
view of the complexity of VEGF signaling. The most intriguing aspect is that cascades of 
kinases, activity of other enzymes and recruitment of adapter proteins converge and branch 
at many points in VEGF signaling, emphasizing how linear pathways can integrate to form a 
complex signal transduction network. If multitasking and integrated signaling go some way 
toward an understanding of the functional versatility of VEGF, it becomes quite complicated 
to elucidate how specific information is processed through these pathways and how signaling 
events are regulated in order to trigger a specific cellular behavior.
2. Historical synopsis of Judah Folkman’s hypotheses and main 
discoveries in the field of tumor angiogenesis
Judah Folkman’s scientific achievements in angiogenesis research revolutionized biomedical 
research and clinical drug development. Until the early 1970s and for some years thereafter, 
the conventional wisdom was that tumor vasculature was an inflammatory reaction to dying 
tumor cells. In 1971, Folkman articulated several “visionary” hypotheses on tumor angiogen-
esis which are now widely accepted. His ideas were based not only on his own work, but also 
on some studies of a small number of investigators [5–7]. As well summarized in a Cancer 
Research Commentary recently written by Augustin [8], Folkman published his hypoth-
esis article in 1971, (i) predicting that tumors would be restricted to microscopic size in the 
absence of angiogenesis, (ii) suggesting that tumors secrete diffusible angiogenic molecules, 
(iii) describing a model of tumor dormancy due to the blocked angiogenesis, (iv) proposing 
the term anti-angiogenesis for the prevention of new capillary sprouts from being recruited 
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into a growing tumor, (v) envisaging the future discovery of angiogenesis inhibitors and (vi) 
proposing the idea that an antibody to a tumor angiogenic factor could be an anticancer drug.
Folkman and collaborators obtained the first evidence of the existence of the avascular and 
vascular phases of solid tumor growth in 1963, on the basis of experiments in isolated per-
fused organs [9]. A rabbit’s thyroid gland was seeded with cancer cells from mice and per-
fused with a blood substitute. Tiny tumors formed, but they grew to the same size, then 
stopped and never became vascularized. When tumors were transplanted into live mice, they 
rapidly vascularized and grew vigorously. This lab work and some clinical observations (in 
particular those regarding retinoblastoma in children) help Folkman develop and sustain the 
hypothesis that tumor growth is angiogenesis dependent.
In the decade following the 1971 report, research in the tumor angiogenesis field attracted 
little scientific interest, but Folkman and his team preserved in their investigations, providing 
convincing evidences for dependence of tumor growth on neovascularization [10–14]. This 
was achieved in particular thanks to the development and use of bioassays devoted to angio-
genesis research, such as the model of eye transplant and chick embryo chorioallantoic mem-
brane. Of note, one of the major steps in allowing scientific appreciation of the role of tumor 
angiogenesis and demonstrating angiogenesis in vitro was developing methods for passage 
of endothelial cells. In 1979, Folkman’s laboratory reported long-term passage of endothelial 
cells [15], and the following year, they demonstrated angiogenesis in vitro using endothelial 
cell cultures exposed to tumor conditioned media [16].
After the developments of the late 1970s, many other scientists entered the field of angio-
genesis and Folkman’s skeptics became his competitors [17]. In particular, the 1980s were an 
intense period of hunting for the hypothesized TAF [8]. In 1983, Dvorak and collaborators 
reported the isolation of a tumor-derived factor that they called “vascular permeability factor” 
(VPF) on the basis of its capability to induce blood vessel leakage [18]. However, at that time, 
VPF was not completely purified and therefore not fully identified. In 1989, Ferrara purified a 
novel angiogenic protein that he termed “vascular endothelial growth factor” (VEGF) on the 
basis of its observed growth-promoting activity toward only vascular endothelial cells [19]. 
Around the same time, Folkman’s laboratory isolated an angiogenic protein that resulted to 
be identical to that purified by Ferrara [20]. By 1990, it was realized that VEGF and VPF were 
in fact the same protein. There is no doubt that it was the discovery of VEGF to set in motion 
a revolution in the field of angiogenic research.
From 1980 to 2005, Folkman’s laboratory reported the discovery of eleven angiogenesis inhibi-
tors, eight of them are endogenous angiogenesis inhibitors [21]. Effort persisted in this area 
and new anti-angiogenic molecules are continuously being developed. They essentially fall 
into two distinct types: (i) antibody directed toward angiogenic factors such as VEGF, for 
example, Avastin (Bevacizumab, Genentech) and (ii) small molecules inhibiting cellular sig-
naling by targeting multiple receptor tyrosine kinases among them VEGFR-2, for example, 
Sutent (Sunitinib, Pfizer) and Nexavar (Sorafenib, Bayer and Onyx Pharmaceuticals) [17].
Targeting VEGF and VEGFR-2 offers benefit to patients with at least some types of cancer 
and provides proof of principle that attacking the vasculature is a valid approach to cancer 
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therapy [22]. At present, however, despite important results, the overall clinical benefits of 
anti-VEGF/VEGFR-2 therapy are still relatively modest: not all cancer patients respond to 
anti-VEGF treatments, and when they do increased survival may only be measured in weeks 
or months [17]. This is realistically due to a number of different and not yet fully clarified 
reasons, which open discussion going beyond the topic of this chapter. Here, we will only 
mention, as reported by Van Epps in 2005, that one of Folkman’s hopes for the future was that 
anti-angiogenesis therapy could be initiated—based on diagnostic biomarkers—even before 
the tumor reveals its location in the body, thus stopping cancer before it really gets started 
[23, 24].
3. VEGF-mediated signal transduction
In vivo angiogenic response to VEGF is mainly mediated via activation of VEGFR-2, expressed 
primarily in endothelial cells. VEGFR-2 activation initiates several intricate signaling paths, 
which eventually lead to different endothelial responses: cell survival, proliferation, migra-
tion, invasion into the surrounding tissue, vascular permeability and vascular inflammation 
[25]. These responses involve (i) a number of pivotal effectors such as phosphoinositide 3 
kinase (PI3K), phospholipase Cγ (PLCγ), SRC, focal adhesion kinase (FAK) and Rho family 
of GTPases; (ii) several multifunctional docking proteins and adaptors; and (iii) VEGFR-2 
partners such as Neuropilin 1 (NRP1), integrins and vascular endothelial (VE)-cadherin. It is 
apparent that these proteins orchestrate a complex signaling network leading to the integra-
tion of the different VEGF-induced endothelial responses that allows tumor angiogenesis to 
take place. Figure 1 illustrates, in a simplified manner, VEGF-mediated signal transduction, 
showing signal core components along with the main well-defined intracellular routes lead-
ing to different endothelial responses.
3.1. VEGFR-2 activation
VEGFR-2 is a tyrosine kinase receptor (RTK). Binding of VEGF to VEGFR-2 promotes recep-
tor dimerization, allowing trans/autophosphorylation of intracellular tyrosine residues. 
Among the 19 tyrosine residues present in the intracellular domain of VEGFR-2, there are five 
major phosphorylation sites: Y951, Y1054, Y1059, Y1175 and Y1214. The Y1054 and Y1059 are 
located in the kinase domain activation loop, and their phosphorylation is critical for recep-
tor catalytic activity [26]. Y951 is located in the kinase insert domain, and its phosphorylation 
serves as a binding site for T cell-specific adaptor (TSAD) also known as VEGFR-2-associated 
protein (VRAP) [27, 28]. The Y1175 and Y1214 are located in the carboxy-terminal domain. 
Phosphorylation of Y1175 creates a binding site for PLCγ [29], p85 subunit of PI3K [30], the 
adaptor proteins SHB [31] and SCK [32]. This residue is well-recognized as a critical mediator 
of VEGFR-2 signaling. Phosphorylated Y1214 has been described to bind the adaptor protein 
NCK [33].
VEGFR-2 activation and downstream signaling are modulated by different mechanisms. The 
main of them involve (i) receptor interaction with NRP1, specific integrins and VE-cadherin 
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(see Section 3.7) and (ii) the activity of the protein tyrosine phosphatases (PTPs) such as 
vascular endothelial PTP (VEPTP), SRC homology 2 domain PTP (SHP2) and PTP1B [34]. 
VEGFR-2 activation may also be influenced by the presence of heparin sulfate glycoproteins 
that modulate VEGF-VEGFR-2 binding and signaling amplitude [35, 36]. Indeed, a change 
in ligand-receptor affinity may highly influence RTK signaling. We recently reported that 
Figure 1. Signal transduction mediated by VEGF/VEGFR-2. Core signaling pathways involved in VEGF-induced (a) cell 
survival and proliferation and (b) vascular permeability and cell migration. See text for details.
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VEGF-VEGFR2 affinity may vary from low to high based on the endothelial cell density state 
that we also reported to influence the number of total and surface VEGFR-2 [37]. In particular, 
by combining wet-lab experiments, theoretical insights and mathematical modeling, we found 
that ligand-receptor affinity is reduced in long-confluent compare to sparse endothelial cells, 
which recapitulate in vitro the condition of quiescent and angiogenic endothelium in vivo.
3.2. PLCγ signaling
Activated VEGFR-2 directly recruits PLCγ, which is in turn phosphorylated [38, 39]. 
Phosphorylated PLCγ hydrolyzes the membrane phospholipid phosphatidylinositol-4,5-bi-
phosphate (PIP2), generating diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This 
latter mobilizes Ca2+ from the endoplasmic reticulum, thus leading to an increase in intracellu-
lar Ca2+. IP3-mediated Ca2+ increase supports DAG-induced activation of PKC, from which it 
is triggered the RAF1-MEK-ERK1/2 mitogen-activated protein (MAP) kinase cascade, that is, 
the best characterized pathway propagated downstream to VEGF/VEGFR-2/PLCγ axis result-
ing, in particular, in endothelial cell proliferation trough the ERK1/2-dependent regulation of 
gene transcription.
Most RTKs are known to utilize the classical GRB2-SOS-RAS activation of the RAF1-MEK-
ERK1/2 cascade. Conflicting results exist in the literature with respect to the interaction of 
VEGFR-2 with SHC or GRB2, which recruit the RAS activating nucleotide-exchange factor 
SOS to the receptor, and the significance of the classical RAS-mediated MAP kinase cas-
cade downstream to VEGFR-2 is unclear [32, 40]. Indeed, it is well-accepted that, after VEGF 
stimulation, most of the MAP kinase activation is mediated via the PLCγ-activated PKC as 
first reported by Takahashi and coworkers [39, 41]. These authors described the pathway as 
RAS-independent; however, considering the same pathway, Shu and colleagues reported the 
involvement of sphingosine kinase (SPK), found to link PKC to RAS activation in a manner 
independent of RAS nucleotide-exchange factor [42].
VEGF-induced activation of PKC also results in activation of protein kinase D (PKD), found to 
influence ERK1/2 activation and cell proliferation [43]. In response to VEGF, gene repressive 
action of histone deacetylases (HDAC) 5 and 7 in endothelial cells is overcome by the PLCγ-
PKC-PKD pathway-dependent HDAC 5 and 7 phosphorylation and nuclear export, resulting 
in the regulation of gene transcription, cell proliferation and migration [44, 45]. Moreover, 
VEGF-induced PKC-dependent activation of PKD has also been reported to induce HSP27 
phosphorylation and mediate cell migration without involving the p38 MAP kinase (p38 
MAPK)/MAP kinase-activated protein kinase 2 signaling cascade [46].
As mentioned above, PLCγ activation induced an increase in intracellular Ca2+. Ca2+ signal-
ing is crucial in VEGF/VEGFR-2 signal transduction, not only for PLCγ/PKC-mediated path-
ways but also for activation of other molecular players such as, in particular, the endothelial 
nitric oxide synthase (eNOS) and the nuclear factor of activated T-cell (NFAT) family of tran-
scription factors. eNOS plays a crucial role in the control of vascular homeostasis and per-
meability; its activity is regulated by a complex combination of protein–protein interactions 
and signal transduction cascades involving Ca2+ mobilization and phosphorylation events 
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[47]. VEGF stimulates both Ca2+ and phosphorylation-dependent regulation of eNOS activ-
ity. VEGF stimulation in endothelial cells first leads to the Ca2+-calmodulin disruption of the 
caveolin-eNOS complex and promotes the association between eNOS and the chaperon pro-
tein HSP90; eNOS-bound HSP90 can then recruit VEGF-activated AKT to the complex, which 
in turn can phosphorylate eNOS, resulting in potentiation of its activity [48]. NFAT proteins—
extensively studied in the immune system—are functional in several cell types, including can-
cer cells, endothelial cells and infiltrating immune cells [49]. The multiple functions attributed 
to NFAT include cell growth, survival, invasion and angiogenesis. These transcription factors 
are activated through a Ca2+- and calmodulin-activated calcineurin-dependent mechanism. 
In endothelial cells, VEGF stimulates receptor-mediated activation of PLCγ leading to an 
increase in intracellular Ca2+, calcineurin activation and NFAT nuclear translocation that in 
turn leads to the transactivation of genes that are essential for angiogenesis [49, 50], such as 
COX-2 resulting in synthesis of PGE2, a mediator of endothelial cell migration and tube for-
mation [51]. Moreover, in endothelial cells, VEGF-mediated NFAT activation induces a gene 
repertoire that includes an inherent inflammatory component, similar to that of interleukin 1 
[52]. In addition, it has been recently reported that endothelial cells decode VEGF-mediated 
Ca2+ signaling patterns to produce distinct functional responses: cell proliferation and cell 
migration involving NFAT and myosin light chain kinase, respectively [53].
VEGFR-2/PLCγ signaling also involves TRPC channels, which are Ca2+-permeable nonselec-
tive cation channels. Indeed, VEGF induces Ca2+ elevation through both Ca2+ release from 
intracellular stores and extracellular Ca2+ entry. In particular, VEGFR-2/PLCγ axis activates 
TRPC3 and TRPC6 in a DAG-dependent manner [54]. TRPC6 has been reported to be required 
for VEGF-mediated Ca2+ increase and the subsequent signaling that lead to processes associ-
ated with angiogenesis, such as cell migration, proliferation and tube formation [55, 56].
Overall, PLCγ appears as a regulator of a number of pathways, leading to cell proliferation 
and migration and contributing to vascular permeability. Thus, a better understanding of its 
downregulation may be of interest in further elucidating the regulation of VEGF-induced 
signaling, as well as in the development of new anti-angiogenic therapies. Indeed, very little 
is known about the regulation of PLCγ activity. Singh and colleagues have been reported that 
VEGF-induced PLCγ ubiquitination inhibits its tyrosine phosphorylation, thus providing a 
negative feedback to prevent sustained PLCγ stimulation [57]. In addition, we have previ-
ously reported the essential role of PTPs on VEGF-induced PLCγ activation, suggesting the 
existence of at least one—not yet characterized—PTP directly targeting PLCγ and counteract-
ing receptor-mediated signal [37].
3.3. PI3K signaling
VEGF/VEGFR-2 axis activates PI3K in different ways, including direct or indirect (i.e., through 
adaptor and scaffold proteins) binding of PI3K to the receptor, and the involvement of SRC 
(see Sections 3.4 and 3.6). The activated PI3K converts the plasma membrane lipid PIP2 to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), and signaling proteins with pleckstrin 
homology (PH) domains accumulate at site of PI3K activation by directly binding to PIP3 
[58]. Among these signaling proteins of particular interest are the serine-threonine kinases 
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AKT and phosphoinositide-dependent kinase 1 (PDK1). Phosphorylation of AKT by PDK1 
and PDK2 allows the full activation of AKT, resulting in the phosphorylation of a number of 
proteins [59]. Other PH domain-containing proteins that are activated by PIP3 include GDP-
GTP exchange factors for the small GTPase RAC [58, 60].
PI3K/AKT pathway is considered the main mechanism by which VEGF induces endothe-
lial cell survival. AKT mediates both short- and long-term cell survival effects by inhibiting 
(through direct phosphorylation) pro-apoptotic proteins such as BAD, caspase 9 and forkhead 
transcription factors, and by upregulating anti-apoptotic proteins such as BCL-2 [61, 62]. In 
1998, Gerber and coworkers were the first to report that VEGF regulates endothelial cell sur-
vival through the PI3K/AKT signal transduction pathway and that VEGF also induces expres-
sion of the anti-apoptotic proteins BCL-2 and A1 in endothelial cells [63, 64]. In the following 
year, Tran and colleagues reported a marked induction of the IAP family anti-apoptotic pro-
teins survivin and XIAP—which inhibit caspase 3, 7 and 9—by VEGF in endothelial cells [65].
Although crucial for its function in cell survival, AKT is not simply a regulator of cell survival 
but a multifunctional protein playing a pivotal role in both cancer cells and endothelial cells. 
In addition to cell survival, AKT activation has been linked to tumor angiogenesis via several 
other biological processes, including vascular permeability, cell proliferation, synthesis and 
release of matrix metalloproteinases and induction of VEGF production by cancer cells [59]. 
Beyond the pro-survival effect and considering the VEGF/VEGFR-2 signal transduction in the 
endothelium, the main contribution exerted by AKT resides in the direct phosphorylation of 
eNOS, thus contributing to the control of endothelial permeability [48, 66].
3.4. SRC and FAK
The SRC family of protein tyrosine kinases (SFKs) plays key roles in regulating signal trans-
duction by a diverse set of cell surface receptors in the context of a variety of cellular envi-
ronments [67]. Endothelial SFKs includes SRC, YES and FYN. Many of the VEGF-mediated 
pathways involve SRC activity. Moreover, SRC is intimately involved in the modulation of the 
activity of FAK through direct phosphorylation (see below). VEGFR-2 activates SRC accord-
ing to different mechanisms: (i) by direct binding to Y951 in the receptor [27], (ii) through the 
adaptor protein TSAD [68] or (iii) involving the scaffold protein GAB1 and GAB2 [69].
VEGF-induced SRC activity is involved in the activation of different signaling proteins, such 
as PI3K, FAK and eNOS. Holmqvist and colleagues reported that activated VEGFR-2 recruits 
SHB and SRC and that this latter phosphorylates SHB, which allows the subsequent activa-
tion of PI3K and phosphorylation of FAK at Y576 [31]. Duval and coworkers reported that 
VEGF induces phosphorylation of VEGFR-2-associated HSP90, which is dependent on recep-
tor internalization and on SRC kinase activation; furthermore, they demonstrated that SRC 
directly phosphorylates HSP90 and that this event is essential for VEGF-stimulated eNOS 
association to HSP90 and thus NO release from endothelial cells [70]. In response to VEGF, 
Src may also activate members of the MAP kinase cascade such as RAF1 [71] and b-RAF [72]; 
this latter is activated in a manner dependent of SRC-mediated phosphorylation of the scaf-
fold protein IQ motif-containing GTPase-activating protein 1 (IQGAP1).
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In parallel with the effect exerted on intracellular signaling proteins, SRC plays a pivotal 
role in the disorganization of cadherin-dependent cell-cell contacts and in integrin-VEGFR-2 
cross-activation. In response to VEGF, SRC phosphorylates VE-cadherin in adherens junc-
tions, allowing endothelial cell migration and inducing vascular permeability [73–76]. 
Mahabeleshwar and coworkers reported that there is an intimate and coordinated relation-
ship between VEGFR-2 and αvβ3 integrin involving SRC activity [77]. In particular, they 
demonstrated that (i) adhesion- and growth factor-induced β3 integrin tyrosine phosphoryla-
tion is directly mediated by SRC, (ii) SRC-dependent β3 integrin tyrosine phosphorylation 
is critical for interaction between VEGFR-2 and β3 integrin, and (iii) SRC mediates growth 
factor-induced β3 integrin activation, ligand binding and αvβ3 integrin-dependent cellular 
adhesion, directional migration of endothelial cells and initiation of angiogenic programming 
in endothelial cells.
As mentioned above, SRC is involved in the modulation of FAK activity through direct phos-
phorylation. The non-receptor tyrosine kinase FAK—well recognized as an important regula-
tor of cell migration—is localized in focal adhesions, established as a consequence of integrin 
ligation to the extracellular matrix. Upon integrin-dependent cell adhesion, phosphorylation 
of FAK and its catalytic activity are stimulated. FAK possesses six tyrosyl residues (i. e., Y397, 
Y407, Y576, Y577, Y861 and Y925) that are differentially phosphorylated by diverse agonists 
and that are implicated in transmitting different signals and effects. Y397 is an autophos-
phorylation site that recruits SH2 domain-containing proteins, including members of SKFs, 
PLCγ and the p85 subunit of PI3K [78]. It appears that SRC is first recruited to Y397 and then 
involved in transphosphorylation of other tyrosyl residues within FAK, such as Y576 and 
Y577; this confers maximal activation of FAK and signaling in response to adhesion [79, 80]. 
In particular, upon VEGF stimulation, Y576 and Y861 are both phosphorylated in a SRC-
dependent manner [31, 81], while Y407 is phosphorylated in a SRC-independent manner that 
involves the recruitment of HSP90 to the receptor, followed by the activation of RHOA and 
that of RHO activated kinase (ROCK) [81]. This results in phosphorylation of FAK on S732 
that allows FAK-related kinase PYK2-mediated phosphorylation of FAK on Y407, promoting 
cell migration [82].
3.5. Rho family GTPases
The RHO family GTPases—shuttling between inactive GDP-bound and active GTP-bound 
forms—include RHO, RAC and CDC42, which are known to regulate primarily the reorga-
nization of actin cytoskeletal systems such as actin stress fibers and focal adhesions, lamel-
lipodia and filopodia, respectively [83]. A growing body of evidence indicates a crucial role 
for VEGF-induced RHO GTPases activity in endothelial cell during the processes involved 
in angiogenesis such as, in particular, cell migration and vascular permeability [84]. VEGF/
VEGFR-2 axis stimulates the activities of RHO [81, 85], RAC [86, 87] and CDC42 [88]. As 
reported in Section 3.4, VEGF-induced RHO activity stimulates FAK activation promoting 
cell migration [81]. VEGF-induced RAC activation has been linked to both endothelial perme-
ability and cell migration. Gavard and Gutkind reported that RAC takes part in a signaling 
pathway by which VEGF stimulation promotes the rapid endocytosis of VE-cadherin, thereby 
VEGF-Mediated Signal Transduction in Tumor Angiogenesis
http://dx.doi.org/10.5772/66764
235
disrupting the endothelial barrier function [86]. In particular, they demonstrated that VEGFR-2 
activates RAC through the SRC-dependent phosphorylation of the nucleotide-exchange 
factor VAV2 and that RAC activation, in turn, promotes the p21-activated kinase (PAK)-
mediated phosphorylation of VE-cadherin resulting in the recruitment of beta-arrestin 2 
to phosphorylated VE-cadherin, thereby promoting its internalization into clathrin-coated 
vesicles and the consequent disassembly of intercellular junctions. To complement this 
study, Garrett and coworkers reported that VEGF-induced SRC-dependent VAV2 phos-
phorylation and downstream activation of RAC1 are also responsible for endothelial cell 
migration and wound closure [87]. The involvement of CDC42 in VEGF signaling has been 
reported in particular by Lamalice and colleagues [33, 88]. They proposed a model accord-
ing to which, upon VEGFR-2 activation phosphorylated Y1214 within the receptor recruits 
the adaptor protein NCK that becomes phosphorylated providing a recruitment site for 
FYN that is also phosphorylated and required for the phosphorylation of NCK and that 
of the p21-activated protein kinase PAK-2, an effector of CDC42; then, this early molecu-
lar complex containing VEGFR-2⋅NCK⋅FYN⋅PAK-2 triggers the sequential activation of 
CDC42 and p38 MAPK leading to actin polymerization, stress fiber formation and endo-
thelial cell migration.
3.6. Key docking, adaptor and scaffold proteins
As it emerges from what above described, it is evident that, beyond a number of kinases 
and other enzymes, VEGFR-2 signaling involves several key docking, adaptor and scaffold 
proteins including SHB, TSAD, NCK, IQGAP1 and GAB1. In the following, we briefly sum-
marize their main involvement downstream to VEGF/VEGFR-2 axis.
The adapter protein SHB contains at least four different domains responsible for protein-protein 
interactions (i.e., the proline-rich motifs in its N-terminus, the phospho-tyrosine binding (PTB) 
domain, potential tyrosine phosphorylation sites and the C-terminal SH2 domain) and has been 
shown to operate downstream of several RTKs exerting versatile effects on a number of signal-
ing pathways [89]. SHB binds to phosphorylate Y1175 in VEGFR-2 and is phosphorylated by 
SRC; this allows the subsequent activation of PI3K and phosphorylation of FAK at Y576 in the 
kinase domain, regulating the migratory response in endothelial cells [31]. Along this pathway, 
it is possible that SHB is required for VEGF-mediated activation of FAK by allowing SRC to 
phosphorylate Y576. Indeed, it has been demonstrated that the PTB domain of SHB can bind 
directly to FAK and regulate its activity in response to FGFR-1 activation in endothelial cells 
[90].
TSAD is an adaptor protein containing a SH2 domain, tyrosines in protein binding motifs 
and a proline-rich domain allowing SH3-dependent interactions. TSAD interacts with and 
modulates the activity of some SFKs such as LCK and SRC [68, 91], and has been found to 
control actin polymerization events in both T cells and endothelial cells [27, 92]. TSAD binds 
to phosphorylate Y951 in VEGFR-2 via its SH2 domain and to SRC via its proline-rich domain. 
TSAD has been reported as an important docking mechanism for SRC to VEGFR-2, involved 
in the regulation of cell migration, endothelial cell junctions and vascular permeability, but 
not cell proliferation [27, 68].
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NCK is an adapter protein consisting of one SH2 domain and three SH3 domains. A main 
function of NCK is to link receptor and receptor-associated tyrosine kinases with proteins 
that directly or indirectly regulate remodeling and reorganization of the actin cytoskeleton 
[93]. According to the model proposed by Lamalice and colleagues, upon phosphorylation on 
Y1214 in VEGFR-2, NCK is recruited to the receptor thus allowing the formation of a molecu-
lar complex containing VEGFR-2⋅NCK⋅FYN⋅PAK-2 that convey the sequential activation of 
CDC42 and p38 MAPK leading to actin polymerization, stress fiber formation and endothelial 
cell migration [33]. Moreover, it has been reported that NCK participates with PAK in the 
signaling pathway by which VEGF stimulates the assembly of focal adhesions [94].
The multidomain scaffold protein IQGAP1 binds to several structural and signaling proteins. 
For example, interactions of the IQGAP1 calponin homology domain (CHD) with F-actin 
and the GAP-related domain (GRD) with small GTPases regulate the cytoskeleton to pro-
mote actin binding or polymerization that regulates cell migration, stability of cell-cell con-
tacts and cytokinesis; moreover, IQGAPs also scaffold molecules form signaling complexes, 
such as components of the MAP kinase cascade, thus promoting their activity [95]. Along 
VEGF signal transduction, IQGAP1 becomes phosphorylated by SRC and activates b-RAF, 
contributing to cell proliferation [72]. Moreover, IQGAP1 has been implicated in regulation 
of cell migration and cell-cell contacts [96, 97]. In particular, Yamaoka-Tojo and colleagues 
suggested that IQGAP1 may function as a scaffold to link VEGFR-2 to the adherens junc-
tions through binding to VEGFR-2 and VE-cadherin/β-catenin complex, thereby dissociating 
α-catenin from the adherens junctional complex and contributing to VEGF-stimulated loss of 
cell-cell contacts in endothelial cell [97].
GAB1 is the prototype of a subfamily of large multiadapter proteins sharing an N-terminal 
PH domain, two proline-rich regions involved in constitutive binding to GRB2 and multiple 
tyrosine phosphorylation sites [98]. Downstream to VEGF/VEGFR-2 axis, GAB1—recruited 
through an amplification loop involving PIP3 and its PH domain—has been proposed to be 
a primary actor in coupling VEGFR-2 to PI3K/AKT [98]. In response to VEGF, it has been 
reported that GAB1 is phosphorylated and associates not only with PI3K, but also with GRB2, 
SHP2, SHC and PLCγ influencing the signaling downstream to VEGFR-2 and, in particular, 
cell migration and capillary formation [99].
3.7. Neuropilin 1, integrins and Vascular Endothelial Cadherin
VEGF signaling is complicated by the fact that VEGFR-2 interact with additional cellular pro-
teins such as, in particular, NRP1, specific integrins and VE-cadherin [100]. This modulates 
the signal strength induced by VEGFR-2 on the basis of the extracellular cues arising from the 
soluble ligand, cell-substratum and cell-cell interactions.
NRP1 is a transmembrane receptor for VEGF and the neuronal guidance cue SEMA3A, 
with essential roles in both vascular and neuronal development, as well as in pathological 
angiogenesis [101, 102]. The precise mechanism of VEGF-VEGFR-2-NRP1 interaction and the 
functional consequences of this molecular complex are still being explored. The most widely 
accepted model of NRP1 function in angiogenesis postulates that it forms a VEGF-dependent 
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complex with VEGFR-2 to enhance the activation of a wide variety of intracellular signal 
transduction pathways, including those that involve ERK1/2, AKT, SRC and p38 MAPK [103]. 
Moreover, it has been reported that NRP1  promotes VEGFR-2 trafficking through RAB11 
vesicles thereby specifying signal output [104].
Integrins link intracellular signaling pathways induced by soluble factor to output elicited by 
cellular interactions with extracellular matrix. Specific integrins, particularly integrin β1 and 
β3, act as important partners for VEGFR-2. An intimate and coordinated relationship between 
VEGFR-2 and αvβ3 has been reported by Mahabeleshwar and coworkers (see Section 3.4) 
[77]. In particular, the relationship between VEGFR-2 and β3 integrin appears to be syner-
gistic, because VEGFR-2 activation induces β3 integrin tyrosine phosphorylation, which, in 
turn, is crucial for maximum phosphorylation of VEGFR-2 [77]. Exposure of endothelial cells 
to matrix-bound VEGF promotes VEGFR-2-integrin β1 complex formation, redistribution to 
focal adhesion, prolonged activation of VEGFR-2 with differential phosphorylation of Y1214 
and extended activation kinetics of p38 MAPK [105].
VE-cadherin is involved in the formation of adherens junctions in endothelial cells and plays 
a crucial role in VEGF signaling. In resting endothelial cells, VE-cadherin complexes with 
VEGFR-2 at cell-cell contacts and attenuates VEGFR-2 phosphorylation through the phospha-
tase DEP1 [106]. Upon VEGF stimulation, VEC is phosphorylated and in turn internalized, 
thereby disrupting the endothelial barrier function (see Sections 3.4 and 3.5).
3.8. VEGFR-2 internalization
It is well known that VEGFR-2 undergoes internalization and trafficking upon VEGF stimu-
lation. Emerging evidences suggest that VEGFR-2 internalization and trafficking are tightly 
controlled processes that influence the sensitivity of endothelial cells to VEGF and the signal-
ing propagated downstream to the receptor. Although the mechanisms regulating VEGFR-2 
internalization and trafficking and their exerted effects on signaling are still not fully under-
stood, it is apparent that a pivotal role is played by VEGFR-2 interaction with specific protein 
partners such as, in particular but not only, VE-cadherin and NRP1.
In endothelial cells, VEGFR-2 is located in different subcellular pools, including receptors dif-
fusely distributed in the plasma membrane, engaged in cell-cell junctions through the inter-
action with VE-cadherin and associated with various intracellular compartments. Resting 
endothelial cells have two surface pools of VEGFR-2: a stable pool that is complexed with 
VE-cadherin, and a flux pool that is constantly cycling between the surface and the endocytic 
compartment in a VEGF independent manner [107, 108]. VE-cadherin prevents internaliza-
tion of VEGFR-2 by physical interaction and recruitment of the DEP-1 phosphatase [106]. 
VEGF stimulation results in clathrin-dependent internalization of VEGFR-2. The clathrin-
coated vesicles fuse with early endosomes and then proceed through a series of steps that 
can either direct their recycling back to the plasma membrane via the fast (RAB4) or slow 
(RAB11) recycling pathways or target them for degradation into lysosome via the RAB7 path-
way [109]. Ballmer-Hofer and colleagues reported that when complexed with NRP1, internal-
ized VEGFR-2 is recycled through RAB4 and RAB11 positive vesicles; while in the absence 
of NRP1, internalized VEGFR-2 bypassed RAB11 vesicles and rapidly accumulated in RAB7 
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vesicles indicative of receptor degradation [104]. They also showed that VEGFR-2 is dephos-
phorylated before entry into the RAB11 compartment and then targeted to the plasma mem-
brane where it presumably initiates a new round of ligand binding and receptor activation 
thereby prolonging VEGF signaling to downstream targets [104]. Furthermore, there are also 
evidences that when activated VEGFR-2—not yet dephosphorylated—is trapped inside endo-
somes, it is still capable of stimulating some downstream signaling proteins such as those 
belonging to the MAP kinase cascade [110].
4. Synopsis of VEGF-induced endothelial responses and their role in 
tumor angiogenesis
VEGF/VEGFR-2 signal transduction leads to six major endothelial responses: cell survival, 
invasion and migration into the surrounding tissue, proliferation, vascular permeability and 
vascular inflammation. These endothelial responses are tightly integrated to allow tumor 
angiogenesis to progress successfully.
Vascular permeability—crucial for normal tissue homeostasis—is a prerequisite for VEGF-
induced angiogenesis. Endothelial permeability is mediated by the so-called transcellular and 
paracellular pathways, that is, solutes and cells can pass through (transcellular) or between 
(paracellular) endothelial cells. Transcellular passage requires cell fenestration and/or a com-
plex system of transport vesicles that includes organelles called vesiculo-vacuolar organelles, 
while the paracellular pathway depends on the coordinated opening and closure of endothe-
lial cell-to-cell junctions, combined with cell retraction. VEGF is involved in both transcellular 
and paracellular permeability. VEGF/VEGFR-2 axis induces increased endothelial perme-
ability mainly through SRC-mediated signaling of VE-cadherin internalization (see Sections 
3.4 and 3.5) that disrupts the endothelial barrier function, and by activation of PLCγ that 
mediates an increase in intracellular Ca2+ resulting in Ca2+-calmodulin-dependent regulation 
of eNOS (see Section 3.2). Activation of eNOS—also achieved by AKT-mediated phosphory-
lation—promotes an increase in vascular permeability by NO production that is followed 
by vasodilatation. VEGF-induced vascular permeability contributes to the dissemination of 
extracellular proteases and the deposition of a fibrin gel provisional stroma that changes the 
extracellular matrix of normal tissues from anti- to pro-angiogenic and stromagenic, favor-
ing and supporting inward migration of endothelial cells and the growth of new endothelial 
sprouts [111]. In addition, the reduced vessel integrity may promote leukocyte extravasation 
and facilitate exit of metastasis from the primary tumors.
VEGF-induced vascular permeability goes in parallel with vascular inflammation. Although 
VEGF is not an inflammatory cytokine, VEGF-induced gene transcription—in particular 
through NFAT activation—includes a conspicuous inflammatory component (see Section 3.2). 
This could conceivably promote attraction of inflammatory cells that may contribute to the 
angiogenic response. Indeed, it is well established that tumor angiogenesis is linked to inflam-
mation. On the one hand, tumor cells can be killed by the immune system; on the other hand, 
tumor can use leukocytes to supports its expansion.
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Endothelial cell invasion into the surrounding tissue is made possible by means of the release 
of MMPs, which degrade the basal membrane and the extracellular matrix and allow the 
migration of endothelial cells to form capillary sprouts. Endothelial cells express different 
MMPs, and it has been reported that their expression is induced by VEGF and regulated by 
Ets transcription factors [112, 113]. Signaling pathways, such as MAP kinase cascade, PI3K/
AKT axis, and Ca2+-specific signals, converge on the Ets transcription factors, controlling their 
activity.
VEGF-induced endothelial cell migration and proliferation are tightly regulated and coor-
dinated spatio-temporal behaviors, which—in parallel with sustained cell survival—enable 
angiogenic sprouting and capillary lumen formation, necessary to create the new vessels 
devoted to support tumor growth and metastasis spread. VEGF-induced endothelial survival 
and proliferation are stimulated primarily via PI3K/AKT and PLCγ/ERK pathways, respec-
tively, involving—as above described—several signaling intermediates. VEGF-induced endo-
thelial cell migration appears to be regulated by a larger number of pathways, including the 
involvement of PLCγ, PI3K, RHO GTPases, SRC and FAK activities.
5. Conclusions
In this chapter, we attempted in particular to describe the best characterized signal transduc-
tion events downstream to VEGF/VEGFR-2 axis involved in tumor angiogenesis. Multiple 
VEGF-induced signaling pathways take part in the promotion of different biological responses 
in endothelial cells. Although it is possible to recognize distinct patterns along VEGF-induced 
signaling, they are intricate, characterized by the involvement of a number of enzymes and 
adaptor/scaffold proteins—whose activity converges and branches at many point—and by the 
presence of VEGFR-2 molecular partners influencing endothelial cell sensitivity to VEGF and 
receptor signal output. This depicts a complex signal network induced by VEGF, where the 
apparent redundancy in operating signaling pathways is likely to reflect a need for a fine-tun-
ing and a differential control of the biological effects in response to VEGF [25]. Although past 
decade has seen an important advancement in our understanding of VEGF signaling, there is 
still a lack of insight in many aspects of VEGF/VEGFR-2 signal transduction, in particular for 
what concerns its fine regulation. A further elucidation of the multifaced VEGF signaling net-
work in the context of endothelial biology is crucial for developing new potential anti-angio-
genic therapies. In parallel with current therapies that directly target VEGF and VEGFR-2, 
agents able to influence key molecular player—proximal, median or distal to VEGFR-2—could 
be of clinical interest.
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